Diffuse Cutaneous Systemic SclerosisPhase 2NCT04166552
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
A Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, run by Emerald Health Pharmaceuticals at 23 sites in 4 countries.
Trial summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc). Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Diffuse Cutaneous Systemic Sclerosis
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 23 sitesin 4 countries
- Study dates
- 11 Jun 2020to Oct 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients male and female ≥18 years and ≤74 years at the time of consent;
- American College of Rheumatology/ European League Against Rheumatism 2013 Criteria for SSc; dcSSc (skin thickening on upper arms, upper legs, or trunk);
- Documented SSc for up to 6 years from the first non-Raynaud's phenomenon with a total mRSS of ≥15;
- No new or increased doses of immunosuppressants medications within 3 months prior to Screening;
- Effective method of contraception for participants and their partners.
Who cannot join
- Severe or unstable Systemic Sclerosis (SSc) or SSc with end-stage organ failure;
- Patient with FVC <60%;
- History of clinically significant medical condition or concurrent medical therapies that would exclude the patient, preclude participation in the clinical trial, influence response to study product, or interfere with study assessments;
- History of gastrointestinal dysmotility requiring total parenteral nutrition or hospitalization within 6 months before Visit 1;
- Any one of the following values for laboratory tests at screening:
- Haemoglobin <9 g/dL;
Show all 11Show fewer
- Neutrophils <1.0 x 10^9/L;
- Platelets <75 x 10^9/L;
- Estimated creatinine clearance <50 mL/min according to the Cockcroft-Gault equation;
- Serum transaminases >2.0 x upper normal limit;
- Total bilirubin ≥1.5 x upper limit of normal.
Trial locations and contacts
23 sites in 4 countries.
23 sites in 4 countries
United States13 sites
Central Florida Pulmonary Group
Altamonte Springs, Florida, 32701
Northwestern University
Chicago, Illinois, 60208
Cleveland Clinic
Cleveland, Ohio, 44195
Care Access Research - Huntington
Huntington Beach, California, 92648
Pacific Arthritis Care Center
Los Angeles, California, 90045
UCLA Division of Rheumatology
Los Angeles, California, 90095
Life Clinical Trials
Margate, Florida, 33063
Novel Clinical Research Center
Miami, Florida, 33186
University of Minnesota
Minneapolis, Minnesota, 55455
Rutgers, The State University of New Jersey
New Brunswick, New Jersey, 08901
Yale University
New Haven, Connecticut, 06511
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona, 85032
Inland Rheumatology Clinical Trials
Upland, California, 91786
Australia6 sites
Royal Adelaide Hospital
Adelaide, 5000
Royal Prince Alfred Hospital
Camperdown, 2050
Footscray Hospital
Footscray, 3011
Griffith University
Gold Coast, 9726
Fiona Stanley Hospital
Murdoch, 6150
Westmead Hospital
Sydney, 2145
Puerto Rico3 sites
Centro Reumatologico
Caguas, 00725
Mindful Medical Research
San Juan, 00918
University of Puerto Rico, Medical Sciences Campus
San Juan, 00935
About this study
Official title: A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).
Read the detailed description
An interventional, double-blind, randomized, intracohort placebo-controlled design will be used to test safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in 36 patients ≥ 18 and ≤ 74 years of age with documented dcSSc. There is a screening period of 28 days, 84 days treatment period, and 28 days follow-up.
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Being tested
- Patients will be randomized to receive EHP-101 or Placebo
- Keywords
- Scleroderma, Systemic sclerosis, EHP-101 Oral Solution, dcSSc, diffuse, pathological processes, connective tissue disease, skin disease
- Medical subject headings
- Scleroderma, Diffuse, Scleroderma, Systemic, Pathologic Processes, Connective Tissue Diseases, Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patients will be randomized to receive EHP-101 or PlaceboDrug
EHP-101 or placebo will be taken once a day
Patients will be randomized to receive EHP-101 or PlaceboDrug
EHP-101 or placebo will be taken twice a day
| Study group | Role | What they receive |
|---|---|---|
| EHP-101 low dose once a day | Experimental | Not described Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo |
| EHP-101 low dose twice a day | Experimental | Not described Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo |
| EHP-101 high dose once a day | Experimental | Not described Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo |
| EHP-101 high dose twice a day | Experimental | Not described Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of Treatment Emergent Adverse Events
This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments.
Measured: Day 113
Secondary outcomes (6)
Treatment effect of EHP-101 compared to placebo as measured by the American College of Rheumatology composite response index in diffuse cutaneous Systemic Sclerosis
The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in modified Rodnan Skin Score (mRSS), Forced Vital Capacity (FVC) % predicted, physician and patient global assessments, and Scleroderma Health Assessment Questionnaire Disability Index (S-HAQ-DI). The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). Subjects are not considered improved (ACR CRISS score = 0) if they develop new: 1) renal crisis; 2) decline in FVC% predicted by 15% (relative) from baseline and confirmed after 1 month; or 3) left ventricular failure (systolic ejection fraction < 45%); or 4) new pulmonary artery hypertension on right heart catheterization requiring treatment.
Measured: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in modified Rodnan Skin Score
The mRSS consists of an evaluation of patient's skin thickness rated by clinical palpation using a 0-3 scale (0 = normal skin; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness with inability to pinch the skin into a fold for each of 17 surface anatomic areas of the body: face, anterior chest, abdomen, and, with right and left sides of the body separately evaluated, the fingers, forearms, upper arms, thighs, lower legs, dorsum of hands and feet. Individual values are summed and defined as the total skin score. Total score is 0 to 51.
Measured: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in forced vital capacity percent predicted
Forced vital capacity (FVC) is a standard pulmonary function test used to quantify respiratory muscle weakness . FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%
Measured: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in physician global assessment score
The Physician Global Assessment of disease activity will be performed using a segmented numerical version of the visual analogue scale in which the physician selects a whole number (0-10 integers) that best reflects the overall disease activity. The numerical rating score is anchored by 2 verbal descriptors, one of "no disease activity" (score of 0) and one of "worse imaginable disease activity" (score of 10), with numbers 1-9 spaced equidistance in between. The physician will select an integer to describe disease activity. The recall period is one week.
Measured: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in patient global assessments score
The Patient Global Assessment will be performed with a segmented numerical version of the visual analogue scale in which the subject selects a whole number (0-10 integers) that best reflects the overall disease activity. The numerical rating score is anchored by two verbal descriptors, one of "no disease activity" (score of 0) and one of "worse imaginable disease activity" (score of 10), with numbers 1-9 spaced equidistance in between. The subject will select an integer to describe disease activity. The recall period is one week.
Measured: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in Scleroderma Health Assessment Questionnaire - Disability Index
S-HAQ-DI includes 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are two or three questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). The eight scores of the eight sections are summed and divided by 8. If one section is not completed by a subject, the summed score is divided by 7. As such, maximum scores can vary with a min of 0. The result is the DI, the disability index or functional disability index. The recall period is one week.
Measured: Day 85 and Day 113
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2019
- Study start11 Jun 2020
- Primary completionJul 2024 (estimated)
- Study completionOct 2024 (estimated)
Why it stopped: Sponsor ceasing all operations due to company's shut down
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diffuse Cutaneous Systemic SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a dose escalation double-blind intracohort trial starting with Cohorts 1 and 2 commencing in parallel and then Cohorts 3 and 4 commencing in parallel
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emerald Health Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04166552
- Sponsor's protocol ID
- EHP-101-SS01
- Status last verified
- Sep 2022
- First submitted
- 6 Nov 2019
- Last updated
- 21 Sep 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis
- ClinicalTrials.gov ID
- NCT04166552
- Acronym / sponsor ID
- EHP-101-SS01
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Keywords
- Scleroderma, Systemic sclerosis, EHP-101 Oral Solution, dcSSc, diffuse, pathological processes, connective tissue disease, skin disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: Sponsor ceasing all operations due to company's shut down
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Emerald Health PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 11 Jun 2020 (actual)
- Primary completion
- Jul 2024 (estimated)
- Study completion
- Oct 2024 (estimated)
- First posted
- 18 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).
Detailed description
An interventional, double-blind, randomized, intracohort placebo-controlled design will be used to test safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in 36 patients ≥ 18 and ≤ 74 years of age with documented dcSSc. There is a screening period of 28 days, 84 days treatment period, and 28 days follow-up.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
- Model description
- This is a dose escalation double-blind intracohort trial starting with Cohorts 1 and 2 commencing in parallel and then Cohorts 3 and 4 commencing in parallel
| Arm | Type | Receives |
|---|---|---|
| EHP-101 low dose once a day | Experimental | Drug: Patients will be randomized to receive EHP-101 or Placebo |
| EHP-101 low dose twice a day | Experimental | Drug: Patients will be randomized to receive EHP-101 or Placebo |
| EHP-101 high dose once a day | Experimental | Drug: Patients will be randomized to receive EHP-101 or Placebo |
| EHP-101 high dose twice a day | Experimental | Drug: Patients will be randomized to receive EHP-101 or Placebo |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients male and female ≥18 years and ≤74 years at the time of consent;
- American College of Rheumatology/ European League Against Rheumatism 2013 Criteria for SSc; dcSSc (skin thickening on upper arms, upper legs, or trunk);
- Documented SSc for up to 6 years from the first non-Raynaud's phenomenon with a total mRSS of ≥15;
- No new or increased doses of immunosuppressants medications within 3 months prior to Screening;
- Effective method of contraception for participants and their partners.
Key exclusion criteria (11 listed)
- Severe or unstable Systemic Sclerosis (SSc) or SSc with end-stage organ failure;
- Patient with FVC <60%;
- History of clinically significant medical condition or concurrent medical therapies that would exclude the patient, preclude participation in the clinical trial, influence response to study product, or interfere with study assessments;
- History of gastrointestinal dysmotility requiring total parenteral nutrition or hospitalization within 6 months before Visit 1;
- Any one of the following values for laboratory tests at screening:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patients will be randomized to receive EHP-101 or PlaceboEHP-101 or placebo will be taken once a day | Drug | EHP-101 high dose once a day, EHP-101 low dose once a day |
| Patients will be randomized to receive EHP-101 or PlaceboEHP-101 or placebo will be taken twice a day | Drug | EHP-101 high dose twice a day, EHP-101 low dose twice a day |
Primary outcome
Incidence and severity of Treatment Emergent Adverse Events
Time frame: Day 113
This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments.
6 secondary outcomes
Treatment effect of EHP-101 compared to placebo as measured by the American College of Rheumatology composite response index in diffuse cutaneous Systemic Sclerosis
Time frame: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in modified Rodnan Skin Score
Time frame: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in forced vital capacity percent predicted
Time frame: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in physician global assessment score
Time frame: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in patient global assessments score
Time frame: Day 85 and Day 113
Treatment effect of EHP-101 compared to placebo in Scleroderma Health Assessment Questionnaire - Disability Index
Time frame: Day 85 and Day 113
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
- Individual participant dataSharing planned: No
Related trials for Diffuse Cutaneous Systemic Sclerosis
RecruitingPhase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
SLE (Systemic Lupus), Lupus Erythematosus, Systemic
RecruitingPhase 1/2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA)
Active, not recruitingPhase 2
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
Active, not recruitingPhase 2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
RecruitingPhase 2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Diffuse Cutaneous Systemic Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
23 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, run by Emerald Health Pharmaceuticals at 23 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 23 sites in United States, Australia, Puerto Rico, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and severity of Treatment Emergent Adverse Events (time frame: Day 113). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.